CD47 upregulation in tumors also significantly contributes to tumor-induced T cell suppression, as the antitumor activity of CD47 blocking treatment is associated with CD11c+ DC activation and is largely T cell-dependent (Liu et al., 2015b, Chen et al., 2020; Li et al., 2020). The gene discussed is ITGAX; the disease is neoplasm.